Simcere Zaiming key facts
as of Oct 2026- Developer and manufacturer of innovative oncology drugs designed for treating cancer patients with unmet clinical needs.
- Simcere Zaiming is valued at approximately $1.2B as of Oct 2026 (last reported valuation).
- It has raised $148.4M; the latest was IPO in Jan 2026.
- Notable investors include CMG SDIC Fund, Youshan Capital, China Taiping Investment, Apricot Capital (Shanghai), Zhonghe Capital.
- Status: In IPO Registration.
Simcere Zaiming's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·Watch Simcere Zaiming: the Monday email on marks, rounds and moves
Simcere Zaiming funding rounds
No funding rounds for Simcere Zaiming are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Simcere Zaiming
5Simcere Zaiming valuation
Simcere Zaiming's last reported valuation was $1.2 billion in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Simcere Zaiming investors
5 investors are on record for Simcere Zaiming, including CMG SDIC Fund, Youshan Capital, China Taiping Investment and Apricot Capital (Shanghai).
About Simcere Zaiming
Developer and manufacturer of innovative oncology drugs designed for treating cancer patients with unmet clinical needs. The company provides drug development services and commercialization capabilities, enabling healthcare providers and patients with access to first-in-class and best-in-class therapeutic solutions.
- Sector
- Healthcare
- HQ
- Haikou, China
- Founded
- 2020
- Employees
- 2,161
- Website
- sparkletx.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.